https://www.bioworld.com/rss en-us Brightpath Biotherapeutics Co. Ltd. has submitted an IND application to the FDA to initiate a phase I trial of BP-2202 in the U.S. (NCT07667868). http://www.bioworld.com/articles/732376 Fri, 03 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732376-brightpath-files-ind-application-for-bp-2202-for-multiple-myeloma Illustration of CAR T Two papers published in the July 1, 2026, issues of Nature and Nature Cancer have reported on preclinical and early clinical data with glycoprotein nonmetastatic melanoma protein B (GPNMB)-targeting CAR T cells in two separate solid tumor types. Nature and Nature Cancer have reported on preclinical and early clinical data with glycoprotein nonmetastatic melanoma protein B (GPNMB)-targeting CAR T cells in two separate solid tumor types.]]> http://www.bioworld.com/articles/732356 Thu, 02 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732356-with-gpnmb-car-t-makes-further-inroads-in-solid-tumors Illustration of CAR T Researchers at East China Normal University and collaborators reported the discovery and optimization of a series of SUCNR1 antagonists for cancer immunotherapy. http://www.bioworld.com/articles/732335 Wed, 01 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732335-sucnr1-antagonist-reverses-tumor-immune-suppression 3D Rendering of tumor microenvironment Aptevo Therapeutics Inc. has been awarded a $1.5 million research grant from the Andy Hill Cancer Research Endowment (CARE) Fund to support IND-enabling work for APVO-451, Aptevo’s trispecific antibody-like immunotherapy candidate for solid tumors. http://www.bioworld.com/articles/732334 Wed, 01 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732334-grant-supports-aptevos-immunotherapy-apvo-451-for-solid-tumors Illustration of cancer cell in crosshairs being destroyed Salubris Biotechnology Co. have reported the development of novel antibody-drug conjugates (ADCs) against glypican-3 (GPC3), an oncofetal glycoprotein overexpressed in approximately 70%-85% of hepatocellular carcinoma (HCC) cases but absent in normal adult tissues. http://www.bioworld.com/articles/732189 Fri, 26 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/732189-gpc3-targeting-adc-for-hcc-shows-superior-efficacy-in-preclinical-models Combotope Therapeutics ApS has established a strategic research collaboration with Boehringer Ingelheim Pharma GmbH & Co. KG that will leverage Combotope’s proprietary SMART-Phage platform to generate highly tumor-selective antibodies for next-generation cancer therapies. http://www.bioworld.com/articles/732136 Thu, 25 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/732136-combotope-and-boehringer-ingelheim-partner-in-cancer Lab glassware and antibodies art concept Researchers from Bristol Myers Squibb Co. (BMS) presented preclinical data on BMS-986453 (tunlucabtagene autoleucel), a dual-targeting BCMA×GPRC5D CAR T-cell therapy, in models of multiple myeloma. http://www.bioworld.com/articles/732132 Thu, 25 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/732132-bmss-dual-car-t-cell-therapy-shows-efficacy-in-multiple-myeloma MPM Bioimpact-spawned K2 Therapeutics Inc. inked a license deal plus option agreement, worth $980.5 million apiece, to gain ex-China rights to two of Antengene Corp. Ltd.’s preclinical anticancer bispecific T-cell engager (TCE) assets. The deal, announced June 21, will grant Singapore-based K2 exclusive rights to develop and commercialize Antengene’s ATG-106 outside of mainland China, Hong Kong, Macau and Taiwan. http://www.bioworld.com/articles/732152 Tue, 23 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/732152-k2-nabs-two-antengene-bispecific-tces-in-2b-license-option-deal Photo of two people shaking hands near lab equipment Rin Institute Inc. has disclosed antibody-drug conjugates consisting of an antibody targeting insoluble fibrin conjugated to MMAE through a plasmin-cleavable linker reported to be useful for the treatment of cancer. http://www.bioworld.com/articles/732123 Tue, 23 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/732123-rin-institute-discovers-new-insoluble-fibrin-targeting-adcs Light chain multiple myeloma (LCMM) is a cancer driven by malignant plasma cells that produce excessive pathogenic free light chains (FLCs) that may cause kidney dysfunction and form amyloid deposits in key organs, thus leading to poor outcomes. Ab Studio Inc.’s CATA-001 is a bispecific antibody targeting both CD38 and aggregated light chains (ALs) designed to deplete CD38+ plasma cells and clear both circulating and tissue-deposited pathogenic FLC aggregates for the treatment of LCMM and AL amyloidosis. http://www.bioworld.com/articles/732095 Mon, 22 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/732095-cata-001-yields-promising-results-for-light-chain-multiple-myeloma Red and blue bispecific antibodies MPM Bioimpact-spawned K2 Therapeutics Inc. inked a license deal plus option agreement, worth $980.5 million apiece, to gain ex-China rights to two of Antengene Corp. Ltd.’s preclinical anticancer bispecific T-cell engager (TCE) assets. The deal, announced June 21, will grant Singapore-based K2 exclusive rights to develop and commercialize Antengene’s ATG-106 outside of mainland China, Hong Kong, Macau and Taiwan. http://www.bioworld.com/articles/732090 Mon, 22 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/732090-k2-nabs-two-antengene-bispecific-tces-in-2b-license-option-deal Photo of two people shaking hands near lab equipment Evaxion A/S has developed EVX-04, an AI-designed DNA vaccine encoding 1β endogenous retroviruses (ERVs)-derived antigenic fragments to induce broad antigen-specific T-cell responses targeting acute myeloid leukemia blasts expressing ERV antigens. http://www.bioworld.com/articles/732031 Fri, 19 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/732031-evaxion-shares-data-from-characterization-of-evx-04 Calidi Biotherapeutics Inc. has received pre-IND regulatory feedback from the FDA on Calidi’s IND-enabling preclinical plans and clinical strategy for CLD-401. The parties agreed on key aspects of the CMC and nonclinical programs, as well as the overall design for the proposed first-in-human study. http://www.bioworld.com/articles/731994 Wed, 17 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/731994-calidi-receives-pre-ind-feedback-from-fda-on-cld-401 Oncolytic virus concept illustration A patent from Jiangsu Hengrui Pharmaceuticals Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. has divulged new antibody-drug conjugates comprising antibodies covalently linked to N-myristoyltransferase 1 (NMT1) inhibitors for potential use in the treatment of cancer. N-myristoyltransferase 1 (NMT1) inhibitors for potential use in the treatment of cancer.]]> http://www.bioworld.com/articles/731971 Tue, 16 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/731971-hengrui-pharmaceuticals-prepares-new-adcs-for-cancer Clinical responses to BCMA- or GPRC5D-directed T-cell engagers in relapsed/refractory multiple myeloma (MM) are often limited by disease relapse and antigen escape, underscoring the need for dual-targeting strategies that enhance durability while mitigating cytokine-driven toxicity. http://www.bioworld.com/articles/731964 Tue, 16 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/731964-bendao-biotechnology-reports-data-on-btl-101-in-multiple-myeloma-models Multiple myeloma art concept Harnessing an oncolytic signal and redirecting it against the tumor itself could be developed as a selective strategy for certain cancer types, as occurs with ErbB hyperactivity, a form of signaling that drives many carcinomas. Inspired by this idea, scientists at Stanford University have engineered a virus that replicates only in ErbB-hyperactive ovarian cancer cells. This allowed them to precisely kill this specific tumor population, achieving greater efficacy and safety than previous oncolytic viruses. http://www.bioworld.com/articles/731852 Tue, 16 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/731852-signal-rewiring-turns-ovarian-cancer-against-itself Illustration of cancer on ovary Researchers from Peking University and Bristar Immunotech Ltd. recently presented the development of a synthetic T-cell receptor and antigen receptor-T (STAR-T) cell therapy targeting leukocyte immunoglobulin-like receptor B4 (LILRB4) for acute myeloid leukemia (AML). http://www.bioworld.com/articles/731934 Mon, 15 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/731934-dual-epitope-anti-lilrb4-star-t-cell-therapy-for-r-r-aml Illustration of acute myeloid leukemia (AML) cells in the blood stream Fortvita Biologics Inc. and Innovent Biologics (Suzhou) Co. Ltd. have jointly reported new antibody-drug conjugates (ADCs) comprising a bispecific antibody or antigen-binding fragments targeting V-set domain-containing T-cell activation inhibitor 1 (VTCN1, B7-H4) and tumor-associated calcium signal transducer 2 (TACSTD2; TROP2) linked to cytotoxic drug. They are described as potentially useful for the treatment of cancer. http://www.bioworld.com/articles/731868 Fri, 12 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/731868-fortvita-and-innovent-patent-new-anti-trop2-b7-h4-adcs Shanghai Ruotuo Biotechnology Co. Ltd. has patented antibody-drug conjugates (ADCs) comprising bispecific antibodies targeting epidermal growth factor receptors (EGFR; ERBB; HER) and receptor tyrosine-protein kinase erbb-3 (ERBB3; HER3) linked to a cytotoxic drug through a linker intended for use in the treatment of cancer. http://www.bioworld.com/articles/731865 Fri, 12 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/731865-shanghai-ruotuo-biotechnology-discovers-new-anti-egfr-her3-adcs A team of investigators at Icahn School of Medicine at Mount Sinai and collaborating institutions aimed to isolate the on-target activity of CAR T cells to target tumor cells. http://www.bioworld.com/articles/731858 Fri, 12 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/731858-tumor-irradiation-promotes-car-t-cell-persistence-and-efficacy-in-lung-metastases-models Cancer cell targeted in crosshairs T-Curx GmbH has obtained clinical trial approval from the Swiss agency Swissmedic for the company’s nonviral lead CAR T program, TCX-001. The first-in-human phase I study will open in Switzerland, and a submission to the EMA will seek to expand the trial to sites in Germany. The study will enroll adults with relapsed or refractory acute myeloid leukemia (AML) and chronic lymphocytic leukemia (CLL), including patients not eligible for stem cell transplantation. http://www.bioworld.com/articles/731835 Thu, 11 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/731835-t-curx-gains-trial-clearance-for-siglec-6-targeted-tcx-001 CAR T cells attacking cancer cell Antengene Corp. Ltd. has obtained IND approval from China’s National Medical Products Administration (NMPA) for ATG-201 for the treatment of B-cell related autoimmune diseases. http://www.bioworld.com/articles/731780 Wed, 10 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/731780-antengenes-atg-201-gains-ind-clearance-in-china 3d rendering of bispecific antibodies Pheon Therapeutics Ltd. has patented antibody-drug conjugates, comprising an antibody targeting CDCP1 covalently linked to a cytotoxic drug through a linker, that are potentially useful for the treatment of cancer. http://www.bioworld.com/articles/731772 Tue, 09 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/731772-pheon-therapeutics-discovers-new-cdcp1-targeting-adcs The University of Oxford and Moderna Inc. have announced authorization by the U.K.’s Medicines and Healthcare products Regulatory Agency (MHRA) to initiate a phase I/II study of mRNA-4194, Moderna’s investigational mRNA-based cancer vaccine for Lynch syndrome. http://www.bioworld.com/articles/731760 Tue, 09 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/731760-modernas-mrna-4194-cleared-for-clinic-for-lynch-syndrome Illustration of messenger RNA About 90% of brain metastases are often limited therapeutically speaking due to the impermeable blood-brain barrier (BBB). Nanocarry Therapeutics Ltd. has presented AxS007, a novel insulin-mediated nanocarrier that delivers multiple copies of trastuzumab and pertuzumab across the BBB, using native insulin as a brain transporter and increasing brain exposure. http://www.bioworld.com/articles/731675 Fri, 05 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/731675-axs007-penetrates-bbb-for-breast-cancer-brain-metastases Illustration of brain in head highlighting the blood-brain barier. Sotio Biotech AS’s SOT-106 has been granted orphan drug designation by the FDA for the treatment of osteosarcoma. SOT-106 is a next-generation antibody-drug conjugate targeting leucine-rich repeat-containing 15 (LRRC15), a clinically validated target broadly expressed across sarcoma subtypes and in tumor-associated stroma. http://www.bioworld.com/articles/731653 Thu, 04 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/731653-sotio-biotechs-sot-106-designated-orphan-drug-for-osteosarcoma Illustration of bone cancer in the knee IMU Biosciences Ltd. has closed its series A at £40 million (US$53.9 million), adding £28.5 million to the initial close in January 2024, and bringing the total raised since the company’s formation in 2021 to £45 million. Since that first close, IMU has built what is claimed as the world’s largest high-definition immune system dataset, with almost 25,000 profiles of healthy volunteers and disease-specific patient cohorts. http://www.bioworld.com/articles/731669 Wed, 03 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/731669-imus-53m-series-a-to-advance-high-definition-immune-profiling-tech Pound sign on tech background CSPC Pharmaceutical Group Ltd. has obtained clinical trial clearance from China’s National Medical Products Administration (NMPA) for SYS-6063, an mRNA-LNP-based dual-target CAR T-cell injection for the treatment of relapsed or refractory systemic lupus erythematosus (SLE). http://www.bioworld.com/articles/731596 Wed, 03 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/731596-cspcs-sys-6063-gains-chinese-trial-clearance-for-sle Concept art for systemic lupus erythematosus R&D IMU Biosciences Ltd. has closed its series A at £40 million (US$53.9 million), adding £28.5 million to the initial close in January 2024, and bringing the total raised since the company’s formation in 2021 to £45 million. Since that first close, IMU has built what is claimed as the world’s largest high-definition immune system dataset, with almost 25,000 profiles of healthy volunteers and disease-specific patient cohorts. http://www.bioworld.com/articles/731528 Tue, 02 Jun 2026 12:00:00 -0400 https://www.bioworld.com/articles/731528-imus-53m-series-a-to-advance-high-definition-immune-profiling-tech Pound sign on tech background Iovance Biotherapeutics Inc. has received IND clearance from the FDA for IOV-5001, a next-generation interleukin-12 (IL-12)-tethered tumor-infiltrating lymphocyte (TIL) therapy. http://www.bioworld.com/articles/731580 Tue, 02 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/731580-fda-approves-ind-for-iovances-til-therapy-iov-5001 Microscope with laptop displaying histology image.